Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.
Standard
Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. / Dahl, Anka; Dautel, P; Meyer, A; Pfüller, Uwe; Schumacher, Udo.
in: BRIT J CANCER, Jahrgang 98, Nr. 1, 1, 2008, S. 106-112.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model.
AU - Dahl, Anka
AU - Dautel, P
AU - Meyer, A
AU - Pfüller, Uwe
AU - Schumacher, Udo
PY - 2008
Y1 - 2008
N2 - This study investigates the effects of mistletoe lectin-I (ML-I) on melanoma growth and spread in vivo. The human melanoma cell line MV3 was xenografted into severe combined immunodeficient mice and vehicle solution or purified ML-I was administered at 30, 150 and 500 ng per kg body weight (20 mice per group) daily. After 19 days, mice were killed, primary tumours (PTs) and lungs were dissected out, and tumour weights, number of lung metastases (LMs), number of tumour-infiltrating dendritic cells (DCs), and apoptosis rates in the melanoma cells and in the DCs were assessed. A 35% reduction of PT weight (P=0.03) and a 55% decrease in number of LMs (P=0.016) were evident for low-dose ML-I (30 ng kg(-1)) treatment but not for higher doses. Mistletoe lectin-I increased apoptosis rates in the melanoma cells of PTs at all doses, while no induction of apoptosis was noted in the LMs. Low-dose ML-I significantly increased the number of DCs infiltrating the PTs (P
AB - This study investigates the effects of mistletoe lectin-I (ML-I) on melanoma growth and spread in vivo. The human melanoma cell line MV3 was xenografted into severe combined immunodeficient mice and vehicle solution or purified ML-I was administered at 30, 150 and 500 ng per kg body weight (20 mice per group) daily. After 19 days, mice were killed, primary tumours (PTs) and lungs were dissected out, and tumour weights, number of lung metastases (LMs), number of tumour-infiltrating dendritic cells (DCs), and apoptosis rates in the melanoma cells and in the DCs were assessed. A 35% reduction of PT weight (P=0.03) and a 55% decrease in number of LMs (P=0.016) were evident for low-dose ML-I (30 ng kg(-1)) treatment but not for higher doses. Mistletoe lectin-I increased apoptosis rates in the melanoma cells of PTs at all doses, while no induction of apoptosis was noted in the LMs. Low-dose ML-I significantly increased the number of DCs infiltrating the PTs (P
M3 - SCORING: Zeitschriftenaufsatz
VL - 98
SP - 106
EP - 112
JO - BRIT J CANCER
JF - BRIT J CANCER
SN - 0007-0920
IS - 1
M1 - 1
ER -
